Browse Companies

RemSleep Holdings Inc. develops the DeltaWave CPAP mask system, a niche device with FDA clearance that recently began commercial sales. Following founder Thomas Wood’s death in early 2026, new leadership has stepped in to guide the company through initial commercialization challenges. The company has seen a sharp decline in revenue over the last fiscal year despite earlier higher sales, while operating losses have widened substantially. Liquidity remains constrained with a sub-1 current ratio and ongoing negative cash flow from operations. Going forward, success hinges on expanding market reach through new FDA applications, distributor partnerships, and institutional accounts under the new CEO’s commercial strategy.

In its latest quarterly filing, Abpro Holdings disclosed continuing operational losses and a transition to OTC Pink trading following Nasdaq delisting due to minimum equity compliance failures. The company’s diversified pharmaceutical portfolio includes insulin analogs, medical devices, and specialty chemicals, but faces steep challenges from regulatory rigor and capital intensity typical of biotech development. Growth depends on advancing product candidates through clinical and regulatory milestones and forging strategic alliances, while liquidity constraints and limited revenue generation pose significant risks to execution.

In its latest quarter, SurgePays maintained a focus on subscriber retention through Lifeline program expansions and digital acquisition despite ongoing financial losses and liquidity challenges. The company operates an integrated wireless MVNO and point-of-sale platform targeting value-conscious, underbanked consumers via a sprawling convenience store network. Growth hinges on expanding subsidized wireless subscribers and enhancing cross-selling within its fintech transaction ecosystem, while risks stem from dependency on government subsidies, substantial debt, and competitive pressures in prepaid wireless markets.

Superstar Platforms Inc. remains in an early operational stage, focusing on building PawnTrust, a mobile-first digital marketplace for pawn shops, while relying primarily on interest income from promissory loans. The latest quarterly filing confirms a sharp increase in operating expenses driven by platform development and supporting loan portfolios, resulting in a widened net loss and liquidity pressures. Strategic growth depends on expanding PawnTrust’s adoption and scaling lending assets through acquisitions, but substantial doubt about continuing as a going concern persists due to the company’s working capital deficiency. Monitoring loan performance metrics, capital raise progress, and platform launch updates will be critical for assessing future viability.

In its Q1 2026 filing, Nauticus Robotics disclosed key amendments to its 2025 asset purchase agreement and loan arrangements, reflecting strategic financial management amid continuing challenges to maintain Nasdaq listing compliance. The company’s core business focuses on specialized underwater robotics for mineral exploration, a capital-intensive niche with substantial technological barriers. While recent equity financing and asset acquisitions enhance product capability and market positioning, constraints on liquidity, equity levels, and stock price impose significant operational risks. Future milestones hinge on delivering robotic solutions at scale, sustaining Nasdaq equity thresholds, and navigating capital structure complexities.

In Q1 2026, QVC, Inc. commenced Chapter 11 bankruptcy proceedings, accelerating obligations under its debt instruments and raising substantial going concern doubts. The company reported a $44 million decline in Adjusted OIBDA year-over-year, reflecting ongoing challenges including restructuring costs and shifting consumer behaviors. Strategically, QVC is advancing the WIN strategy—focusing on enhanced customer engagement across digital platforms and streamlined operations—while consolidating physical operations by closing its St. Petersburg campus. The company’s multi-channel platform combining televised shopping, e-commerce, social commerce, and streaming remains uniquely positioned but is under pressure from digital competitors and changing viewing habits. Liquidity is supported by over $1.4 billion in cash but constrained by restrictive covenants and a noncompliant net leverage ratio. Execution of the court-approved restructuring plan will be essential to stabilize capital structure and sustain growth amid economic uncertainties impacting discretionary demand.

Texas Ventures Acquisition III Corp’s latest quarterly filing reveals operational challenges typical for a blank check company nearing its business combination deadline, including potential trust account indemnity risks and limited liquidity outside the trust. The appointment of Troy Rillo as CEO, alongside his continuing CFO role, marks a governance strengthening amid a competitive SPAC environment. The firm’s business model remains focused solely on completing an initial business combination within Nasdaq’s 36-month framework, with growth contingent on executing this transaction. Execution risks, liquidity constraints, and timing pressures remain paramount considerations for stakeholders in this next phase.

Cytosorbents Corp has demonstrated significant revenue growth over recent years fueled by its proprietary polymer technology, but persistent operating losses reflect ongoing R&D investment and regulatory challenges. The company’s DrugSorb-ATR device encountered an FDA De Novo application denial in April 2025, followed by an appeal process and plans for a resubmission with new real-world data expected mid-2026. Despite these regulatory hurdles and market acceptance risks, Cytosorbents retains a strong liquidity position with a current ratio above 2, though negative cash flows continue. Capital allocation remains conservative with no dividends or buybacks, focusing on funding clinical and regulatory milestones.

Q/C Technologies, having shifted from pharmaceuticals to laser-based computing hardware in late 2025, is actively advancing its qc-LPU100 prototype aimed at energy-efficient blockchain mining and AI workloads. The company’s exclusive licensing of LightSolver’s photonic technology underpins its IP moat but commercialization remains contingent on successful prototype validation and regulatory approvals. Industry adoption is uncertain given nascent technology risks and evolving regulatory frameworks. Q/C Technologies’ near-term outlook hinges on execution milestones that will demonstrate product viability and unlock growth potential.

My Size, Inc. operates an integrated platform encompassing AI-based size and fit solutions, Amazon third-party retail operations, European recommerce services, and Israeli brand distribution. Historically, the company has experienced minimal revenue with significant operating losses, but a net income swing into profitability in 2025 reflects emerging operational shifts. Future growth depends on expanding U.S. commercial agreements for Naiz Fit technology, scaling recommerce business driven by EU regulations, and cross-selling among business units. However, persistent operating cash flow deficits and geopolitical instability in Israel pose material risk to continued execution.

In its latest 10-Q filing, QVC Group disclosed critical operational shifts and a strategic reorganization aimed at stabilizing the business during ongoing Chapter 11 bankruptcy. The company’s core multi-channel retail model, integrating televised shopping and digital commerce through its QxH, QVC International, and Cornerstone Brands segments, underpins its market presence amid restructuring challenges. Growth efforts focus on enhancing customer engagement via the WIN plan and consolidating operations such as merging QVC and HSN platforms. Persistent liquidity pressures and high net leverage pose notable risks but also frame key milestones to monitor including emergence from bankruptcy and execution of growth initiatives.

Nature's Miracle Holding Inc. operates in the Controlled Environment Agriculture (CEA) hardware market, providing LED grow lights, grow media, and dehumidifiers to indoor growers in North America. Its latest quarterly filing reveals declining revenues and persistent operating losses since 2022, raising significant doubt about the company’s ability to continue as a going concern. Despite owning an established branded product line 'eFinity' and a real estate asset generating rental income, the company faces severe liquidity constraints amplified by a concentrated customer base, supply chain vulnerabilities, and intense industry competition. The transition to profitability hinges on restoring revenue growth while managing costs amid structural challenges.

United Health Products, Inc. develops CelluSTAT®, a patented hemostatic gauze cleared for superficial bleeding but currently seeking FDA Premarket Approval (PMA) for Class III surgical applications. The company has recorded no product revenue since at least 2022, sustaining operating losses driven by regulatory, clinical, and development expenses. Its near-term growth depends on resolving regulatory deficiencies identified by the FDA and securing commercial partnerships or strategic transactions. Liquidity remains tight, with financing arrangements from Alumni Capital supporting ongoing operations. The company faces significant risks including regulatory uncertainty, competitive pressures, and operational challenges tied to manufacturing and internal controls.

Atlantic International Corp. operates primarily through its subsidiary Lyneer Staffing Solutions, providing workforce staffing solutions with integrated AI technology across North America and Europe. The company has pursued an aggressive acquisition strategy, notably acquiring Staffing 360 Solutions and Circle8 Group, enhancing its presence in industrial and IT staffing sectors. Despite expansion and innovation strides, Atlantic faces significant financial headwinds including sustained operating losses, complex joint debt obligations with its principal stockholder IDC, liquidity constraints, and a going concern qualification in its audited financials. The recent preferred stock offering aims to bolster working capital but substantial refinancing remains necessary. Monitoring debt restructuring progress, client retention, and operational efficiency improvements will be key.

Mitesco, Inc. has ceased operations of its unprofitable healthcare clinic segment and now operates as a holding entity managing two main subsidiaries: Centcore, LLC, which offers co-location based data center and cloud services, and Vero Technology Ventures, LLC, focused on AI-driven software products including a sales automation tool scheduled for launch in late 2026. While this strategic refocus aligns with digital transformation trends in the cloud infrastructure and AI sectors, Mitesco faces significant liquidity constraints, substantial legacy obligations from discontinued businesses, and competitive pressure from established data-centric firms. Financial restructuring efforts have converted past debts into equity instruments, but very limited cash and high liabilities indicate ongoing challenges in maintaining operational flexibility. Success hinges on expanding data services capacity with minimal capital outlay, advancing AI applications to market, securing stable customer subscriptions, and managing the continued resolution of legal and financial legacy issues.

Vivakor’s May 2026 10-Q underscores ongoing infrastructure growth, including the Omega Gathering Pipeline expansion, alongside advancing environmental remediation operations. The company’s integrated midstream business model leverages trucking, pipeline, terminaling, and commodity marketing to capture margins across key U.S. basins, anchored by long-term contracts with minimum volume commitments. However, significant liquidity constraints and concentrated customer exposure remain near-term risks that could impact execution and growth prospects. Monitoring operational ramp-up milestones and financing outcomes will be critical to assessing Vivakor’s ability to scale its integrated platform effectively.

CirTran Corporation’s latest quarterly filing reveals modest operational improvements with a net loss reduction and early cash sustainability indicators, though significant liquidity constraints prevail. The company’s contract manufacturing model centers on turnkey services for consumer products across diverse segments, notably benefiting from exclusive manufacturing and distribution rights for HUSTLER®-branded tobacco-related products. CirTran's competitive position is characterized by its niche licensing moat combined with global manufacturing partnerships, but it faces concentrated customer risk and financial leverage pressures. Drivers of growth include expanding product diversification within licensed brands and leveraging international production capabilities, while key risks involve working capital deficits and dependency on related-party financing.

Solidion Technology Inc., formed via a SPAC merger in early 2024, has rapidly advanced its position in advanced battery materials, achieving a near doubling of revenue in 2025 driven by commercialization efforts. The company’s expansive patent portfolio and proprietary production methods underline its technological moat in silicon anodes and solid-state batteries. However, operating losses remained substantial despite revenue growth, fueled by high R&D and SG&A expenses as the company scales technology development and sales efforts. Cash runway is critically short, with only about $205,000 in cash reported at year-end and recurring negative cash flows raising serious concerns about going concern status. Solidion’s future growth hinges on successful scale-up with manufacturing partners and securing additional capital to fund accelerated expenditures. The ongoing liquidity constraints and lack of dividends or buybacks spotlight material financing risks ahead.

American Strategic Investment Co. owns a concentrated commercial real estate portfolio predominantly in Manhattan, totaling approximately 0.7 million rentable square feet as of end-2025. Since terminating its REIT election at the start of 2023, the company has expanded its asset scope but faces significant headwinds including mortgage covenant breaches and liquidity constraints. Despite recognizing a one-time $47.9 million gain from a consensual foreclosure of a major property in 2025, the company reported a net loss of $21.2 million and negative operating cash flows for the year. The capital structure is stressed with $251 million of mortgage notes payable, including accelerated debt and ongoing defaults on certain properties, raising substantial doubts about going concern. Watch for refinancing efforts, property disposals, and management’s ability to stabilize operational cash flows.

Nocera, Inc. reported in its latest 10-Q filing that it currently fails to meet Nasdaq's minimum stockholders’ equity requirement, triggering an imminent compliance deadline. The company continues its pivot away from manufacturing recirculation aquaculture systems (RAS), focusing on fish trading and commission-based e-commerce facilitation across multiple geographies. While geographic diversification and strategic investments in e-commerce firms may offer growth avenues, Nocera confronts substantial risks including negative equity, ongoing losses, and volatile commodity markets. The near-term outlook is dominated by the urgency of Nasdaq listing compliance efforts and operational restructuring.

Mannatech Inc reported a substantial net loss of $15.2 million in FY2025 following a volatile earnings trajectory marked by operating income fluctuations and constrained cash flows. The company’s liquidity position remains tight with a current ratio slightly above 1.0, supported by related-party loan extensions to ease short-term pressures. Capital allocation activities show minimal dividends and no repurchases since FY2024, reflecting cautious cash management. Enhanced governance protocols focus on cybersecurity and IT risk oversight by the Board’s dedicated committee, addressing material operational risks.

In its latest quarterly filing, Vivos Therapeutics underscored ongoing operational transitions as it strives to meet Nasdaq’s equity requirements through recent equity raises, while scaling a novel business model focused on acquisition and management of sleep medical practices. The firm’s proprietary oral appliances and The Vivos Method remain central, but the shift toward medical service organizations (MSOs) and dental service organizations (DSOs) branded as Sleep and Airway Medicine Centers (SAMC) represents a strategic repositioning targeting higher-margin healthcare services revenue alongside device sales. This transformation aims to broaden patient access and deepen provider integration amid competitive and regulatory complexities. Capital constraints and execution risks present near-term challenges that will require diligent monitoring as the company pursues growth via acquisitions, alliances, and expanded clinical programs.

BioForce Nanosciences Holdings, Inc. reported zero revenues and a critically low current ratio of 0.01 as of Q1 2026, reinforcing its precarious liquidity position. Its business model centers on natural vitamins and nutritional supplements aimed at promoting active lifestyles but lacks any recent sales traction or product market penetration. Operating losses and accumulated deficits exceed $162 million, with survival hinging on obtaining new capital amid a highly fragmented and competitive nutritional supplements sector. Key operational risks stem from insufficient working capital, going concern qualifications, and execution uncertainties tied to fundraising success.

Gorilla Technology Group Inc. has evolved from video content solutions to a global AI-driven provider of Security Intelligence, Network Intelligence, Business Intelligence, and IoT platforms. Its integrated ecosystem combines hardware, software, and services, notably hybrid edge-to-datacenter AI infrastructure and GPU-as-a-Service offerings. While Gorilla posted $74.7 million in revenue for FY2024 — up 15% from the prior year — profitability remains elusive with a substantial net loss of $64.8 million. Growth prospects center on multi-year government and enterprise contracts, including sizable deals in Southeast Asia and India forming a $7 billion+ pipeline. Capital allocation has focused on financing expansion through equity raises amid continued investment needs.

Canaan Inc. nearly doubled revenue from $269 million in 2024 to about $530 million in 2025, fueled by strong sales of industrial and home-use Bitcoin mining machines and scaling its Bitcoin mining operations. Despite this impressive revenue trajectory, the company continues to grapple with significant operating losses driven by high R&D and supply chain costs, as well as inventory management expenses. Persistent negative operating cash flows highlight challenges in converting revenue growth into sustainable profitability, compounded by dependencies on third-party foundries and regulatory uncertainty. Going forward, Canaan's expansion in home-use miners and strategic mining business development offer growth avenues, but margin recovery and operational stability remain key hurdles.

Allied Energy's May 2026 10-Q reveals ongoing operational progress backed by a solid liquidity profile, evidenced by a current ratio of 5.67 and positive net income reported through the end of 2025. The company remains focused on leveraging its majority stake in WeLife Technology as a key growth driver, although limited disclosure creates opacity around its precise market positioning and revenue mechanics. Risks persist mainly due to this lack of transparency and the execution demands typical for smaller reporting companies. Near-term updates on integration progress and clearer business segment disclosure will be critical to assess Allied’s trajectory.

Vystar Corp operates in three distinct yet niche areas: Vytex natural rubber latex, RxAir UV-based air purifiers, and Fluid Energy Conversion green energy technologies. Despite proprietary technology and some FDA clearances, the company has a limited operating history with volatile revenue and continuing net losses, burdened by thin liquidity and heavy operational costs. Vystar’s growth hinges on expanding sales of its products and capital raises, while its small scale and competitive markets pose ongoing challenges. The firm maintains substantial accumulated deficits and negative equity, with no dividend payments anticipated in the foreseeable future.

Loan Artificial Intelligence Corp. remains a developmental-stage company without current revenue, focusing on completing the acquisition of Hong Technology Co. Limited, a Hong Kong-based AI and intelligent hardware firm. The May 2026 quarterly filing confirms receipt of audited financial statements for the target, enabling advancement in the merger process, but highlights severe liquidity pressures with zero current assets against nearly $200K in current liabilities. The company faces intense competition from better-capitalized M&A players and regulatory complexities tied to cross-border transactions. Success hinges on finalizing definitive agreements, securing capital, and integrating the acquired business to initiate revenue generation and sustainable growth.

Limitless X Holdings Inc. operates across health, wellness, entertainment, and technology through four subsidiaries focusing primarily on a direct-to-consumer dietary supplement business enriched by celebrity branding. The company's historical growth has been driven by rapid expansion of product lines and channel diversification but offset by substantial operating losses and near-term liquidity challenges. Future growth is dependent on successfully scaling retail presence, integrating AI-driven digital wellness tools, and international expansion while navigating sector regulatory complexities. Limitless X's aggressive capital deployment since 2021 has yet to achieve profitability, with mounting net losses significantly exceeding revenues and a strained balance sheet posing execution risks.

Veritone, Inc. has seen a drastic contraction in revenue from $149.7 million in 2022 to roughly $23.2 million in 2025, primarily due to its strategic divestiture of Veritone One in late 2024 aimed at concentrating on its proprietary aiWARE AI platform. Despite this pivot, financial strains persist, with significant operating losses and cash flow deficits compounded by a subordinated liquidity profile and going concern risks. The technological moat anchored by aiWARE’s open architecture remains a key asset, but future growth hinges on overcoming execution challenges within a rapidly evolving AI landscape.

BioRegenx's Q1 2026 filing underscores ongoing liquidity pressures characterized by a severe current liabilities surplus and low current ratio, despite incremental operational progress. The company’s business revolves around multiple subsidiaries producing AI-powered diagnostic tools, patented supplements, and digital wellness platforms, targeting a fragmented healthcare and consumer market. While clinical trials and tech integration present growth avenues, competitive forces in medical devices and digital health, along with regulatory complexity, pose significant execution risks. Monitoring financing developments alongside clinical and product milestones will be critical for assessing near-term sustainability.

Mosaic ImmunoEngineering’s latest 10-Q reveals termination of its exclusive cowpea mosaic virus (CPMV) licensing, a foundational technology that had underpinned the company’s immunotherapy pipeline. This pivotal change necessitates a strategic repositioning focused on acquiring new clinical-stage assets and leveraging proprietary AI technologies to identify innovative immunotherapy combinations. While the company pursues opportunistic licensing deals, notably with Oncotelic Therapeutics for necroptosis vascular disruptive agents, it faces substantial capital constraints and regulatory hurdles characteristic of early-stage biotech. Its business model remains centered on outsourced manufacturing and research-driven pipeline development without commercial revenues. The path forward hinges on securing additional technologies and financing to sustain operations.

FOXO Technologies Inc. reported persistent capital access issues in its most recent quarterly filing, including FINRA’s denial of a proposed reverse stock split essential for raising additional financing. Despite these constraints, FOXO continues to develop its integrated business model comprising rural healthcare delivery, behavioral health services, life science biospecimen sourcing, and early-stage epigenetic labs. The company’s ownership of a Critical Access Hospital and established biospecimen logistics anchors a unique but capital-intensive niche in underserved markets. Major risks center on liquidity shortfalls, regulatory complexities, and integration execution risks. Upcoming milestones include resolution of the reverse split appeal and new capital raises critical for operation funding.

GIVBUX, Inc. reported no material changes in legal or risk factors in its latest Q1 2026 filing, continuing to focus on advancing its GivBux Super App. The app integrates payment processing, social networking, blockchain, and charitable giving to differentiate itself in the competitive fintech mobile wallet space. Despite innovative multi-functionality and a growing user base, the company faces severe liquidity constraints with a current ratio near 0.02 and net losses from previous periods. Growth hinges on expanding merchant partnerships, increasing user engagement, and successful execution of planned app improvements, while key risks include intense competition from better-capitalized players and operational scaling challenges.

Mentor Capital, Inc.'s most recent quarter underscores a clear pivot to classic energy assets, marked by the acquisition of fractional royalty interests in the Permian Basin. While this move aligns with its historical roots and offers revenue with minimal operational expenses, the company's ongoing auditor changes pose short-term filing and financing risks. Its business model as a holding company focused on opportunistic energy investments provides a low-cost exposure angle but relies heavily on external funding and market conditions. Sustained growth will depend on securing financing, warrant exercise dynamics, and capitalizing on energy sector demand drivers amid competitive pressures.

Castor Maritime Inc. has sustained revenue growth through a dual business model integrating shipping operations and asset management. Despite a notable rise in top-line revenue by 23.5% in 2025, operating income dipped into negative territory due to increased voyage expenses and off-hire periods. The company’s fleet utilization, combined with transaction fees via MPC Capital, supports diversified income streams that mitigate sector cyclicality. Castor’s liquidity remains robust with over $150 million in cash at year-end 2025, while strategic debt repayments and sale-leaseback arrangements reflect active capital structure management. Investors should monitor dry docking schedules, vessel sales, and charter rate trends as near-term catalysts influencing operational performance.